Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia

Tissue Antigens

Volumn 68, Issue 1, 2006, Pages 19-27

  Joyner, D E ^a   Damron, T A ^b   Aboulafia, A ^c   Bokor, W ^a   Bastar, J D ^a   Randall, R L ^a  

^a UNIVERSITY OF UTAH   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

hMAGE family; hMAGEA4 mRNA; Mesenchymal tissues; Real time PCR; Sarcoma

Indexed keywords

CANCER TESTIS ANTIGEN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MESENCHYMOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SARCOMA; TRANSLATION INITIATION;

ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; GENE EXPRESSION; HUMANS; MALE; MUSCLE, SKELETAL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, CONNECTIVE TISSUE; RNA, MESSENGER; RNA, NEOPLASM; SARCOMA; TESTIS;

EID: 33745157163     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00618.x     Document Type: Article

References (30)

1. van der Bruggen P Traversari C Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 : 254 : 1643 7.
2. Xiao J Chen H-S. Biological functions of melanoma- associated antigens. World J Gastroenterol 2004 : 10 : 1849 53.
3. Chomez P De Backer O Bertrand M De Plaen E Boon T Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001 : 61 : 5544 51.
4. Barker PA Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res 2002 : 67 : 705 12.
5. Scanlan MJ Gure AO Jungbluth AA Old LJ Chen Y-T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002 : 188 : 22 32.
6. Van den Eynde BJ Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 1997 : 27 : 81 6.
7. Jungbluth AA Busam KJ Kolb D et al. Expression of MAGE-antigens in normal tissue and cancer. Int J Cancer 1999 : 85 : 460 5.
8. Ries J Schultze-Mosgau S Neukam F Diebel E Wiltfang J. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol 2005 : 26 : 817 24.
9. Vantomme V Dantinne C Amrani N et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004 : 27 : 124 35.
10. Chianese-Bullock KA Pressley J Garbee C et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005 : 174 : 3080 6.
11. Lüftl M Schuler G Jungbluth AA. Melanoma or not? Cancer testis antigens may help. Br J Derm 2004 : 151 : 1213 8.
12. Kwon S Kang SH Ro J Jeon C-H Park J-W Lee ES. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma. Cancer 2005 : 104 : 251 6.
13. Dong H-L Li Z-S Ye J et al. Identification of HLA-A2-restricted CTL epitope encoded by the MAGE-n gene of human hepatocellular carcinoma. Cancer Biol Ther 2004 : 3 : 891 8.
14. Atanackovic D Altorki NK Stockert E et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004 : 172 : 3289 96.
15. Dalerba P Frascella E Macino B et al. MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer 2001 : 93 : 85 90.
16. Ayyoub M Taub RN Keohan M-L et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004 : 4 : 7.
17. Van den Eynde BJ van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997 : 9 : 684 93.
18. Marchand M Punt CJA Aamdal S et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003 : 39 : 70 7.
19. Bettinotti MP Panelli MC Ruppe E et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12: 170-8. Int J Cancer 2003: 105 : 210 6.
20. Weber JS Hua FL Spears L Marty V Kuniyoshi C Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999 : 22 : 431 40.
21. Sadanaga N Nagashima H Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001 : 7 : 2277 84.
22. Toungouz M Libin M Bulté F et al. Transient expansion of peptide-specific lymphocytes producing IFN-γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 2001 : 69 : 937 43.
23. Lesimple T Moisan A Carsin A et al. Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects. Cancer Immunol Immunother 2003 : 52 : 438 44.
24. Marchand M van Baren N Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999 : 80 : 219 30.
25. Hersey P Menzies SW Coventry B et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005 : 54 : 208 18.
26. Yamana H. Immunotherapy for esophageal carcinoma. Nippon Geka Gakkai Zasshi 2002 : 103 : 376 80.
27. Castiglione F Toschi F Bernaschi M et al. Computational modeling of the immune response to tumor antigens. J Theor Biol 2005 : 237 : 390 400.
28. Sudo T Kuramoto T Komiya S Inoue A Itoh K. Expression of MAGE genes in osteosarcoma. J Orthop Res 1997 : 15 : 128 32.
29. Lee SY Obata Y Yoshida M et al. Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA 2003 : 100 : 2651 6.
30. Roeder C Schuler-Thurner B Berchtold S et al. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res 2005 : 296 : 314 9.